Alopecia Areata

Currently Enrolling Alopecia Areata Studies

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

• Population: Adolescents Children between 6 to 12 years of age
• Study Condition: Participants must have a diagnosis of severe AA, with ≥50% scalp hair loss, no evidence of terminal hair regrowth within the previous 12 months.
• Study Design: This study investigates ritlecitinib in children adolescents with severe AA and a baseline SALT score of 50 or greater. A Phase 3 randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and tolerability of ritlecitinib in pediatric participants. This study will include 2 ritlecitinib dosage levels (50 mg and 30 mg) and matching placebo. The participants will be assessed for study eligibility at the screening visit after assent is obtained (as applicable) from the participant and informed consent is obtained through their parents or legal guardians. Participants will complete screening, be randomized then receive 1 of the 2 dosage levels of ritlecitinib or placebo, to be taken orally for 24 weeks.
• Reimbursement will be provided